40.50
1.00%
+0.40
Xenon Pharmaceuticals Inc stock is currently priced at $40.50, with a 24-hour trading volume of 320.66K.
It has seen a +1.00% increased in the last 24 hours and a -5.06% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $39.92 pivot point. If it approaches the $41.00 resistance level, significant changes may occur.
Previous Close:
$40.10
Open:
$40.02
24h Volume:
320.66K
Market Cap:
$3.06B
Revenue:
$13.17M
Net Income/Loss:
$-182.39M
P/E Ratio:
-16.27
EPS:
-2.49
Net Cash Flow:
$-150.94M
1W Performance:
+1.55%
1M Performance:
-5.06%
6M Performance:
+30.06%
1Y Performance:
+2.48%
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
604-484-3300
Address
200 3650 Gilmore Way, Burnaby
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-04-24 | Initiated | Citigroup | Buy |
Dec-08-23 | Initiated | Robert W. Baird | Outperform |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
Dec-14-22 | Initiated | Goldman | Buy |
Dec-12-22 | Initiated | Cowen | Outperform |
Nov-28-22 | Initiated | Wells Fargo | Overweight |
Oct-19-22 | Initiated | Raymond James | Outperform |
Aug-29-22 | Initiated | BofA Securities | Buy |
Jul-21-22 | Initiated | JP Morgan | Overweight |
Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
Oct-02-20 | Initiated | SVB Leerink | Outperform |
Jul-21-20 | Initiated | Needham | Buy |
Jun-01-20 | Resumed | Jefferies | Buy |
Mar-25-20 | Initiated | Wedbush | Outperform |
Jan-08-20 | Initiated | William Blair | Outperform |
Sep-20-19 | Initiated | Guggenheim | Buy |
Aug-08-18 | Reiterated | Stifel | Buy |
Mar-13-17 | Initiated | Jefferies | Buy |
Oct-21-16 | Initiated | Stifel | Buy |
Sep-26-16 | Initiated | Guggenheim | Buy |
Apr-14-16 | Reiterated | Jefferies | Buy |
Oct-30-15 | Resumed | Jefferies | Buy |
Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire Inc.
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
GlobeNewswire Inc.
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
GlobeNewswire Inc.
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Zacks Investment Research
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Xenon Pharmaceuticals Inc (XENE) Revenue 2024
XENE reported a revenue (TTM) of $13.17 million for the quarter ending September 30, 2022, a -33.65% decline year-over-year.
Xenon Pharmaceuticals Inc (XENE) Net Income 2024
XENE net income (TTM) was -$182.39 million for the quarter ending December 31, 2023, a -45.48% decrease year-over-year.
Xenon Pharmaceuticals Inc (XENE) Cash Flow 2024
XENE recorded a free cash flow (TTM) of -$150.94 million for the quarter ending December 31, 2023, a -48.97% decrease year-over-year.
Xenon Pharmaceuticals Inc (XENE) Earnings per Share 2024
XENE earnings per share (TTM) was -$2.72 for the quarter ending December 31, 2023, a -33.33% decline year-over-year.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Cap:
|
Volume (24h):